Development and validation of two nomograms for predicting overall survival and Cancer-specific survival in prostate cancer patients with bone metastases: a population-based study

Table 2 Demographic and clinical characteristics of patients with PABM in CSS group

Characteristics	All samples		Training		Validation		P
Characteristics	N	Percentage (%)	N	Percentage (%)	N	Percentage (%)	P
Age
< 70	640	57.10%	459	57.90%	181	55.40%	0.437
> 70	480	42.90%	334	42.10%	146	44.60%	0.437
Race
White	856	76.40%	593	74.80%	263	80.40%	0.240
Black	220	19.60%	166	20.90%	54	16.50%
Asian/Pacific Islander	34	3%	26	3.30%	8	2.40%
American Indian/Alaska Native	10	0.90%	8	1%	2	0.60%
Marital status
Married	690	61.60%	477	60.20%	213	65.10%	0.119
other	430	38.40%	316	39.80%	114	34.90%	0.119
Year of diagnosis
2010–2014	790	70.50%	545	68.70%	245	74.90%	0.039
2015–2018	330	29.50%	248	31.30%	82	25.10%	0.039
T stage
T1	394	35.20%	283	35.70%	111	33.90%	0.551
T2	413	36.90%	297	37.50%	116	35.50%
T3	153	13.70%	107	13.50%	46	14.10%
T4	160	14.30%	106	13.40%	54	16.50%
N stage
N0	742	66.20%	516	65.10%	226	69.10%	0.193
N1	378	33.80%	277	34.90%	101	30.90%	0.193
PSA
< 4	32	2.90%	22	2.80%	10	3.10%	0.381
4–10	85	7.60%	67	8.40%	18	5.50%
10–20	134	12%	92	11.60%	42	12.80%
> 20	869	77.65%	612	77.20%	257	78.60%
Gleason score
< =6	12	1.10%	8	1%	4	1.20%	0.625
7 (3 + 4)	58	5.20%	43	5.40%	15	4.60%
7 (4 + 3)	78	7%	59	7.40%	19	5.80%
8	240	21.40%	162	20.40%	78	23.90%
9	732	65.40%	521	65.70%	211	64.50%
Chemotherapy
Yes	198	17.70%	145	18.30%	53	16.20%	0.407
No/Unknown	922	82.30%	648	81.70%	274	83.80%	0.407
Radiation
Yes	1099	98.10%	778	98.10%	321	98.20%	0.949
No	21	1.90%	15	1.90%	6	1.80%	0.949
Surgery
Local	119	10.60%	90	11.30%	29	8.90%	0.264
No	993	88.70%	696	87.80%	297	90.80%
Prostatectomy	8	0.70%	7	0.90%	1	0.30%
lung
Yes	85	7.60%	59	7.40%	26	8%	0.769
No	1035	92.40%	734	92.60%	301	92%	0.769
liver
Yes	58	5.20%	41	5.20%	17	5.20%	0.984
No	1062	94.80%	752	94.80%	310	94.80%	0.984
brain
Yes	19	1.70%	16	2%	3	0.90%	0.195
No	1101	98.30%	777	98%	324	99.10%	0.195

ISSN: 1471-2490